https://www.otcmarkets.com/filing/html?id=13137144

New Post Public Reply Private Reply Replies (1) Message Board
trding sjacobs26 #1455
442
https://www.otcmarkets.com/filing/html?id=131...aPm86zh-yh

That January was a new note. The June 26th note become convertible 6 months later, first payment on December 27th, and each month on the 26th-28th after, see quote below. I trade many otc stocks and can spot these note being converted from years of watching and learning. They put a MM, maybe vndm or cfgn on the bid for support and another mm on the ask at 2500 shares to sell. Then the shares are sold in blocks randomly through the day. Alps is the MM on the ask selling, they will move the ask up or down depending on volume. Alps and vndm showed up right when these conversions started, was not there before, so that is how I know they are using them. Paulson investors use NITE in the past, I suspect the TA that allows shares to be sold directly routes through NITE, so it shows up when any of the Paulson people sell directly from the TA. Anyway, someone hits the ask enough they move ask price up, if not, they sell these blocks to the bid, dropping randomly, until their monthly allotment is gone. If you are asking why is someone selling at 47c, that is crazy, then it was probably them. Also, they never sell into vndm, but if someone else sells into that bid support, vndm in this case, then they usually start dropping big blocks on the bid. I’ve picked up many of cheap otc shares in other stocks waiting for that to happen, putting my big bids a few pennies below vmdm. I’m not sure why they do it, but it is very common, which looks like happened around 3pm today.

With other stock, I usually jump in right when the conversion is done, but most of those are toxic unlike these notes, which is monthly payments over 24 months here. For example I just bought 2M drng at .0011 yesterday, convertible note, down from over 1c, when the conversation stops, I’m looking for a double at least. Win some lose some, sometimes it bounces back over 1c quickly and I get a 10x bagger in 1 week. Another Gmer, the last note just finished, so I am buying 500k under 1c, expecting a bounce to 4c or 5c with the next news hopefully in April or May. The trick is to catch the final convertible shares being sold, knowing the signs the conversion is done from watching l2, reading financials for note conversion dates and, looking at o/s increases, counting after market t-trades, then usually a bounce after they finish, at least temporarily until the next note starts converting. Also it helps to know their conversion price, because they usually never sell below that price, but might sell all the way down to that price. Sometimes they buy back up 10% in share price, which signals other MM algorithms to start buying, increasing volume, so they can sell more into the higher volume. It is possible the big volume spike here two weeks ago was from that.

Quote:
On December 27, 2018, the Company received a redemption notice from the holder of the Company’s convertible note issued on June 26, 2018 requesting the redemption of $100,000 of the outstanding balance thereof. In satisfaction of the redemption notice, the Company issued 255,532 shares of Common Stock to the note holder in accordance with the terms of the convertible note. Following the redemption, the outstanding balance of the convertible note, including accrued but unpaid interest, was approximately $5.9 million.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sarepta Under Scrutiny: KSF's Investigation Deepens

Updated Category News Views 3

A Troubling Chapter for Sarepta Therapeutics It's not every day that a company's dirty laundry gets hung out for all to see, especially when we're talking about Sarepta Therapeutics, a player in the rare disease treatment space. But that's exactly where we find ourselves this fine day—a bit like kicking a hornet's nest, if you ask me. Led by the former Louisiana...

Continue Reading
Cyngn: A Deep Dive into Its Robust 24-Patent Portfolio

Updated Category News Views 4

Cyngn's Growing Patent Portfolio: A Robust Defense Ah, Cyngn Inc., the hotshot in AI-powered autonomous vehicle tech, is flexing its muscles with a solid 24-patent stash. We're talking about a company that's not messing around, racking these up since they decided to dive head-first into solving the brain-busting problems of the industrial sector. Their strategy? Build and...

Continue Reading
New Concierge Pediatric Care at Weill Cornell Launches

Updated Category News Views 3

A New Way Forward in Pediatric Care When a couple of seasoned pediatricians decide it's time for something fresh, eyes and ears perk up. Enter Dr. Paul W. Chung and Dr. Jane E. Rosini, diving headfirst into a revolutionary pediatric concierge program courtesy of Concierge Choice Physicians (CCP). We're talking a substantial shake-up at Weill Cornell Medicine, aiming to...

Continue Reading
Postal Service Defends New Rule Amid Speculation

Updated Category News Views 3

USPS Navigates Election Mail Controversies The U.S. Postal Service has found itself in the eye of a political storm, thanks to the latest Federal Ballot Mail Rule. Led by Postmaster General David Steiner, the USPS is setting the record straight amidst swirling misinformation and skepticism about its recent actions. This is not just a postal service under scrutiny—it's a...

Continue Reading
Acepodia's ACE723 Clears FDA Hurdle for Hepatocellular Push

Updated Category News Views 6

Unexpected Developments from Acepodia Folks keeping a keen eye on the biotech scene might just raise an eyebrow at Acepodia's latest move. The FDA has given their nod to ACE723, an ambitious dual-payload antibody-drug conjugate (ADC) designed to wrangle with those stubborn cases of unresectable or metastatic hepatocellular carcinoma (HCC). This isn't just another day in...

Continue Reading
BellRing Brands Faces Legal Probe; Fiduciary Duties Questioned

Updated Category News Views 1

What's Stirring at BellRing Brands? Hey, no time like the present to dive headfirst into this mess BellRing's found itself in. On the heels of a lackluster sales forecast, just announced about a year ago, Kahn Swick & Foti's got their magnifying glasses out, searching for any shady dealings by those running the show at BellRing Brands, LLC. Why Is BellRing in the Hot...

Continue Reading
S&P 500 Shuffle: Bloom, Illumina, Everpure Join Frenzy

Updated Category News Views 5

Index Shuffles Stir Market Pot Changes are afoot, folks, with the movers and shakers of the market indices stepping into the spotlight. A lot is brewing with S&P Dow Jones Indices making significant switches effective September 21, 2026—right before trading heats up. You better believe it's affecting more than a couple of tickers. Who's In and Who's Out? If you’ve...

Continue Reading
TrailBlazer Magazine Snags a Tribune for In-House Design

Updated Category News Views 4

Who Knew? Design Awards Aren't Just for Pretty Pictures TrailBlazer Magazine gets a pat on the back from GDUSA's 2026 Inhouse Design Awards, a nod to top-notch design work. With over 4,000 entries across the board, getting into the top 10 percent is like finding a steakhouse with zero line on a Friday night. Not exactly common, right? Design Worth Cheering For The winning...

Continue Reading
MMRO Achieves URAC AI Accreditation, Ensures Compliance

Updated Category News Views 4

A Milestone in Healthcare AI: MMRO's New Accreditation When AI in healthcare gets an official nod from the big guys like URAC, it's a significant moment. We're talking about Managed Medical Review Organization, Inc. (MMRO), a firm that's just earned the URAC Artificial Intelligence in Health Care Accreditation. Now, this isn't just some rubber stamp; it's a testament to...

Continue Reading
Dimerix Locks Down A$34M Loan: No Shareholder Dilution

Updated Category News Views 2

Dimerix Grabs Non-Dilutive Funds amid Kidney Trials Here we go with Dimerix's latest move, folks. They roped in A$34 million through a cozy get-together with lenders from Australia and the U.S. What's the kicker? This cash won't touch shareholder equity. So, breathe easy, investors. It's a rare feat to pull off non-dilutive funds these days, especially in the biopharma...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming the Narcolepsy Market: Innovations Ahead

Updated Category News Views 166

The Evolving Landscape of the Narcolepsy Market The narcolepsy market is undergoing significant changes as it shifts from merely managing symptoms to developing targeted therapies that tackle the root causes of the disorder. Traditionally, treatments focused on alleviating symptoms, but advancements now emphasize addressing the underlying neurochemical issues, primarily...

Continue Reading
UBS Analysts Share Insights on China Stocks Strategies

Updated Category News Views 242

UBS Analysts Offer Insights on China's Equity Market In a recent discussion, UBS strategists have expressed a level of caution regarding China's equity market as they look into the evolving landscape of 2025. It's noted that local A-share investors appear hesitant to seize buying opportunities, influenced by a myriad of factors that create uncertainty in the market....

Continue Reading
Palisade Bio's Special Meeting Cancellation: What You Need to Know

Updated Category News Views 133

Palisade Bio Cancels Special Meeting of Stockholders Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company making strides in developing innovative treatments for autoimmune, inflammatory, and fibrotic diseases. Recently, the company announced an important decision regarding its special meeting of stockholders. The special meeting, originally...

Continue Reading
Vivendi Reports Impressive 4.5% Revenue Growth in 2024

Updated Category News Views 123

Remarkable Revenue Growth for Vivendi Vivendi has announced an impressive increase in its revenues for the first nine months of 2024, emphasizing strong growth across its core business sectors. The company reported a revenue increase of 4.5% at constant currency and perimeter, compared to the same period in the previous year. This growth showcases the resilience and...

Continue Reading
Revolution in Home Renovation Arrives with Spray-Net Franchise

Updated Category News Views 226

Fresh Approach to Home Makeovers Home remodeling isn’t just about slapping on a new coat of paint anymore. In February 2026, Spray-Net is gearing up to launch in Allen, Texas, shaking things up in the renovation game. This venture represents a leap forward—not only for franchise growth but for homeowners who are sick and tired of traditional, drawn-out renovations....

Continue Reading